U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06886360) titled 'Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)' on March 14.
Brief Summary: Open-label, multi-center, phase III trial. Oral treatment with 1500 mg norucholic acid in Primary Sclerosing cholangitis
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Primary Sclerosing Cholangitis
Intervention:
DRUG: norucholic acid
500 mg norucholic acid film-coated tablets; 3 tablets/day
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Dr. Falk Pharma GmbH
Published by HT Digital Content Services with permission from Health Daily Digest....